---
title: "FENGBEI BIOTECH: 35.9 million new shares will be listed on the main board on November 5, highlighting multiple risks"
description: "FENGBEI BIOTECH announced that its 35.9 million new shares will be listed on the Shanghai Stock Exchange main board on November 5, 2025, with the stock code 603334. The company reminds investors to pa"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/263997998.md"
published_at: "2025-11-03T11:07:40.000Z"
---

# FENGBEI BIOTECH: 35.9 million new shares will be listed on the main board on November 5, highlighting multiple risks

> FENGBEI BIOTECH announced that its 35.9 million new shares will be listed on the Shanghai Stock Exchange main board on November 5, 2025, with the stock code 603334. The company reminds investors to pay attention to various risks in the early stages of listing, including the relaxation of price fluctuation limits, low circulating shares, valuation, and margin financing risks. The issuance price is set at 24.49 yuan per share, corresponding to a diluted price-to-earnings ratio of 30.47 times for 2024 after deducting non-recurring items, which is lower than the industry average and the average level of comparable companies

FENGBEI BIOTECH announced that the company's ordinary shares in RMB will be listed on the main board of the Shanghai Stock Exchange on November 5, 2025, with the stock code 603334. After the initial public offering, the total share capital will be 14.35 million shares, with 3.59 million shares being issued, all of which are new shares. The company reminds investors to pay attention to the investment risks in the early stages of listing, including the relaxation of price fluctuation limits, low circulating shares, valuation, margin financing, and other risks. The issuance price is 24.49 yuan per share, corresponding to a diluted price-to-earnings ratio of 30.47 times after deducting non-recurring items for 2024, which is lower than the industry average and the average level of comparable companies

### Related Stocks

- [603334.CN - FENGBEI BIOTECH](https://longbridge.com/en/quote/603334.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Deep-sea fish break the mold with novel visual system | New research has identified a novel type of visual cell in deep-sea fish, blending features of rods and cones, adapted f | [Link](https://longbridge.com/en/news/276218702.md) |
| Xintela Completes Clinical Study With XSTEM In Difficult-To-Heal Leg Ulcers | Xintela AB :COMPLETES CLINICAL STUDY WITH XSTEM IN DIFFICULT-TO-HEAL LEG ULCERSPRIMARY GOAL TO INVESTIGATE SAFETY AND TO | [Link](https://longbridge.com/en/news/275910672.md) |
| Godavari Biorefineries Dec-Quarter Consol PAT 82.5 Million Rupees | Godavari Biorefineries Ltd :GODAVARI BIOREFINERIES DEC-QUARTER CONSOL PAT 82.5 MILLION RUPEESGODAVARI BIOREFINERIES LTD  | [Link](https://longbridge.com/en/news/275909082.md) |
| Dozens of Democrats call for removal of newly appointed OB-GYNs from vaccine advisory panel | Dozens of Democratic lawmakers are urging the removal of two OB-GYNs, Dr. Adam Urato and Dr. Kimberly Biss, from the Adv | [Link](https://longbridge.com/en/news/275769715.md) |
| 07:43 ETFDA Grants Breakthrough Device Designation to Two Rapid Tests Targeting Critical Drug-Resistant Pathogens | The FDA has granted Breakthrough Device Designations to two rapid tests by NG Biotech and Hardy Diagnostics targeting cr | [Link](https://longbridge.com/en/news/276228838.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.